Evolent Health, Inc.: Form 10-Q for the period ended Sep 30, 2021
Filed with the SEC on Nov 4, 2021 and accepted by EDGAR at Nov 3, 2021, 18:24 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Selling, general and administrative | 3 months2021-07-01 to 2021-09-30 | $51.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2021-01-01 to 2021-09-30 | $152.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2021-07-01 to 2021-09-30 | −$6.6m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2021-01-01 to 2021-09-30 | −$30.2m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2021-07-01 to 2021-09-30 | $6.4m | us-gaap:InterestExpense |
| Interest expense | 9 months2021-01-01 to 2021-09-30 | $19.0m | us-gaap:InterestExpense |
| Income tax | 3 months2021-07-01 to 2021-09-30 | $234.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2021-01-01 to 2021-09-30 | $936.0k | us-gaap:IncomeTaxExpenseBenefit |
| Diluted EPS | 3 months2021-07-01 to 2021-09-30 | −$0.15 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2021-01-01 to 2021-09-30 | −$0.37 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2021-07-01 to 2021-09-30 | −$0.15 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2021-01-01 to 2021-09-30 | −$0.37 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2021-07-01 to 2021-09-30 | 85,800,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2021-01-01 to 2021-09-30 | 85,306,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2021-01-01 to 2021-09-30 | −$27.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2021-09-30 | $252.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2021-09-30 | $478.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2021-09-30 | $1.25bn | us-gaap:Assets |
| Current liabilities | At period end2021-09-30 | $367.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2021-09-30 | $646.0m | us-gaap:Liabilities |
| Long-term debt | At period end2021-09-30 | $211.1m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2021-09-30 | $26.7m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2021-09-30 | $607.5m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001628908-21-000149. Last ingested by Listed: Nov 15, 2026, 04:22 ET. Listed shows no prices and gives no investment advice.